GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór: rak trzustki, jelita grubego lub wątroby (w badaniu tkanki)
- •Choroba zaawansowana (przerzuty), której nie można operować w celu całkowitego wyleczenia
- •Mierzalne zmiany nowotworowe widoczne w badaniach obrazowych
- •Pacjent nigdy nie otrzymywał chemioterapii na tym etapie choroby
- •Wiek minimum 18 lat
- •Dobry ogólny stan zdrowia (zdolność do codziennych czynności)
- •Wystarczająca funkcja wątroby, nerek i szpiku kostnego
- •Dostępna próbka tkanki nowotworowej do badań genetycznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- September 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Arizona Cancer Center
Tucson, United States
Trial contact
Rachel EB Jarrett, MPH
Prisca Zimmerman
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.